Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07535606 | A Study to Evaluate ALN-4915 in Adult Healthy Volunteers | PHASE1 | RECRUITING | 44 | — | — | Mar 2, 2026 | Jul 31, 2027 | May 14, 2026 | 1 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| ALN-4915 | EXPERIMENTAL | Participants will be administered a single dose of ALN-4195. |
| Placebo | PLACEBO_COMPARATOR | Participants will be administered a single dose of placebo. |
| Name | Type | Description |
|---|---|---|
| ALN-4915 | DRUG | ALN-4915 will be administered subcutaneously (SC) |
| Placebo | DRUG | Placebo will be administered SC |
Inclusion Criteria: * Is willing and able to complete all study assessments Exclusion Criteria: * Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>upper limit of normal (ULN) * Has total bilirubin \>ULN * Has no history of invasive infection by an encapsulated organism * H...